Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Lord

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Nature Communications|November 5, 2024
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancerM T Herrera-Abreu, J Guan, U Khalid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2022
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancerK Van Baelen, T Geukens, M Maetens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2022
Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785]K Van Baelen, T Geukens, M Maetens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2024
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancerE Harvey-Jones, M Raghunandan, L Robbez-Masson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2025
Clinical challenges and proposed solutions for patients with invasive lobular breast cancerK Van Baelen, E Sawyer, J Van Cauwenberge, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Nature Communications|November 5, 2024
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancerM T Herrera-Abreu, J Guan, U Khalid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2022
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancerK Van Baelen, T Geukens, M Maetens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2022
Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785]K Van Baelen, T Geukens, M Maetens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2024
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancerE Harvey-Jones, M Raghunandan, L Robbez-Masson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2025
Clinical challenges and proposed solutions for patients with invasive lobular breast cancerK Van Baelen, E Sawyer, J Van Cauwenberge, et al.
Pageof 4